All conditions

Non-Alcoholic Fatty Liver Disease

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1592
Trials on record
218
Recruiting now
9
Australian sites
15
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Non-Alcoholic Fatty Liver Disease →

Get alerts when Non-Alcoholic Fatty Liver Disease trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease, often shortened to NAFLD, is a condition where fat builds up in the liver in people who drink little or no alcohol. The liver is a vital organ that performs hundreds of jobs in the body, including filtering the blood and helping with digestion. In most people with NAFLD, the fat build-up causes no immediate symptoms and no serious damage. However, in some people the condition can progress to a more inflamed or scarred state, which is why doctors monitor it carefully over time.

NAFLD is surprisingly common in Australia. Estimates suggest that roughly one in three Australian adults may have some degree of fatty liver. It tends to occur more often in people who are living with obesity, type 2 diabetes, high cholesterol, or high blood pressure, though it can also affect people who do not have any of these conditions. It affects adults and children across all backgrounds, making it one of the most widespread liver conditions in the country.

When it comes to managing NAFLD, doctors generally focus on addressing the underlying factors that contribute to fat accumulating in the liver. This typically involves conversations about nutrition, physical activity levels, and managing related health conditions such as diabetes or high cholesterol. In many cases, gradual and sustainable weight loss has been shown to make a meaningful difference to liver health. Your doctor or a specialist such as a hepatologist or gastroenterologist will be the right person to talk to about what approaches suit your individual circumstances.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Non-Alcoholic Fatty Liver Disease in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Non-Alcoholic Fatty Liver Disease currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Non-Alcoholic Fatty Liver Disease.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Non-Alcoholic Fatty Liver Disease by country. Australia is highlighted.

Showing the top 10 of 60 countries with trial sites.

Clinical trials for Non-Alcoholic Fatty Liver Disease

Showing 224 of 224 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT02217475 · Tobira Therapeutics, Inc. Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 30 June 2016
🇦🇺 AU🇧🇪 BE🇫🇷 FR🇩🇪 DE Hong Kong🇮🇹 IT🇵🇱 PL🇪🇸 ES +2 more

**Who might be able to join this trial:** - You are between 18 and 75 years old - A liver biopsy has confirmed you have a liver condition called NASH (a form of fatty liver disease), with a disease activity score of 4 or higher, with points scored in each part of the scoring system - Your biopsy also shows some scarrin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03008070 · Inventiva Pharma Phase 2 · 16 countries Completed
Completed Phase 2 Est. completion 20 February 2020
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE +8 more

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed with a specific liver condition called NASH (non-alcoholic steatohepatitis), confirmed by a liver biopsy taken within 6 months before the screening visit or during screening, showing a certain level of liver fat, infl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05945537 · Inipharm Australia Pty Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 May 2025
🇦🇺 AU

Who might be able to join this trial: **For all parts of the trial:** - People who are able and willing to attend all required study visits at the trial site. - People who are willing to give written consent to participate after the study has been fully explained to them. - People whose kidneys are working at a normal...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06215716 · Akero Therapeutics, Inc Phase 3 · 18 countries Recruiting
Recruiting Phase 3 Est. completion 1 February 2033
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇳 IN🇮🇱 IL🇮🇹 IT +10 more

Who might be able to join this trial: - Men and women (who are not pregnant or breastfeeding) between 18 and 80 years old at the time of their screening visit - People who have had, or currently have, at least 2 of these 4 conditions: obesity, abnormal cholesterol or fats in the blood, high blood pressure, or high fast...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06318169 · 89bio, Inc. Phase 3 · 27 countries Recruiting
Recruiting Phase 3 Est. completion 1 February 2029
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇫🇷 FR +19 more

Who might be able to join this trial: - Men or non-pregnant women between 18 and 80 years old at the time of signing the consent form - People who have had a liver biopsy confirming a specific liver condition called MASH, with a moderate level of liver scarring (classified as stage F2 or F3) - People with a body mass i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06419374 · 89bio, Inc. Phase 3 · 24 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇫🇷 FR🇩🇪 DE +16 more

Who might be able to join this trial: - People who are male or non-pregnant female, aged 18 to 75 years old at the time of signing the consent form - People who have been diagnosed with type 2 diabetes for at least 3 months before the screening visit, or who have at least 2 metabolic risk factors (confirm with trial si...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06528314 · Akero Therapeutics, Inc Phase 3 · 19 countries Recruiting
Recruiting Phase 3 Est. completion 1 February 2030
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇱 CL🇫🇷 FR🇩🇪 DE🇮🇳 IN +11 more

**Who might be able to join this trial:** - (Group 1) You have confirmed liver scarring at the most advanced stage (cirrhosis), caused by a fatty liver disease related to metabolic conditions (NASH/MASH), diagnosed through a biopsy, with a certain level of disease activity shown by the biopsy results - (Group 2) You h...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06632444 · Boehringer Ingelheim Phase 3 · 36 countries Recruiting
Recruiting Phase 3 Est. completion 27 December 2031
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +28 more

**Who might be able to join this trial:** - You are 18 years old or older (or the legal adult age in your country) at the time you give consent - You have been diagnosed with MASH (a liver condition also known as non-alcoholic fatty liver disease) with a disease activity score of 4 or higher - Your body weight has been...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06632457 · Boehringer Ingelheim Phase 3 · 36 countries Recruiting
Recruiting Phase 3 Est. completion 5 June 2029
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +28 more

**Who might be able to join this trial:** - You are 18 years of age or older (or the legal age of consent in your country, if higher) - Your body mass index (BMI) is 27 or above (or 25 or above if you are of Asian background) — BMI is a measure based on your height and weight - You have been diagnosed with a specific...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07165028 · Eli Lilly and Company Phase 3 · 34 countries Recruiting
Recruiting Phase 3 Est. completion 1 August 2030
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN +26 more

**Who might be able to join this trial:** - Your liver contains a certain level of fat (at least 8%), which would be measured before joining (confirm with trial site) - A specific liver health score called an ELF score falls within a certain range, suggesting a moderate level of liver scarring or damage (confirm with t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07221227 · GlaxoSmithKline Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 29 March 2028
🇦🇺 AU🇨🇦 CA Hong Kong🇯🇵 JP🇳🇿 NZ Puerto Rico🇸🇦 SA🇹🇼 TW +1 more

**Who might be able to join this trial:** - You are able to understand and willing to sign a consent form before any study activities begin - You are between 18 and 75 years old at the time of joining - You have been diagnosed with 2 or more features of metabolic syndrome (such as high blood pressure, high blood sugar...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02855164 · Novartis Pharmaceuticals Phase 2 · 17 countries Terminated
Terminated Phase 2 Est. completion 6 April 2020
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇳 IN +9 more

**Who might be able to join this trial:** - You are 18 years old or older, male or female - You are willing and able to sign a written consent form to participate - For Parts A and B: You have been diagnosed with a specific type of liver disease called NASH (fatty liver with inflammation), confirmed by a liver biopsy t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03053050 · Gilead Sciences Phase 3 · 27 countries Terminated
Terminated Phase 3 Est. completion 19 June 2019
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇫🇷 FR🇩🇪 DE +19 more

**Who might be able to join this trial:** - You have had a liver biopsy that shows a specific type of liver scarring related to a condition called NASH (fatty liver disease with inflammation), at a stage called "bridging fibrosis" (F3) - Your liver enzyme levels (ALT) are not too high — no more than 8 times the upper...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03053063 · Gilead Sciences Phase 3 · 22 countries Terminated
Terminated Phase 3 Est. completion 6 May 2019
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE Hong Kong🇮🇳 IN +14 more

**Who might be able to join this trial:** - A liver biopsy has confirmed you have NASH (a type of fatty liver disease) with advanced scarring (the most severe stage, called F4 or cirrhosis), as reviewed by a specialist reader. - Your liver enzyme levels (ALT) are not extremely elevated — specifically, no more than 8 t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02808312 · Gilead Sciences Phase 1 · 2 countries Completed
Completed Phase 1 Est. completion 16 October 2018
🇳🇿 NZ🇺🇸 US

Who might be able to join this trial: - You may be eligible if you have mildly reduced liver function or normal liver function (Cohort 1). - If you have mild liver problems, your liver condition must have been measured as "mild" using a standard scoring system, and your condition must not have gotten worse in the 2 mon...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00575133 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇨🇭 CH

Who might be able to join this trial: - People who have been diagnosed with fatty liver disease confirmed through a tissue sample (biopsy) Who may not be able to join: - People with a history of significant alcohol use - People who have viral hepatitis (such as hepatitis B or C) - People who have autoimmune hepatitis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02193295 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2034
🇺🇸 US

Who might be able to join this trial: - People who are healthy, not physically active on a regular basis, non-smoking, and not taking any medications except possibly birth control pills. - People whose hematocrit (a measure of red blood cells in the blood) is above 35%. - People with no whole-body or organ-related dise...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02206841 · Seoul National University Boramae Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇰🇷 KR

Who might be able to join this trial: - You have been diagnosed with fatty liver disease confirmed by a tissue sample (biopsy) - You have been diagnosed with fatty liver disease confirmed by a scan or imaging test (such as an ultrasound or MRI) Who may not be able to join: - You have a history of drinking significant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02422238 · Maastricht University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2017
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called NAFLD (a build-up of fat in the liver), confirmed by an MRI scan or a tissue sample (biopsy). - Your Body Mass Index (BMI) is 30 or higher (meaning you are classified as obese based on height and weight). - You are between...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02863757 · Humanity and Health Research Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have had a liver biopsy confirming chronic hepatitis B (CHB) and/or non-alcoholic fatty liver disease (NAFLD) at the start of the study - People of Chinese ethnicity - People who have been followed up or monitored for more than 12 months Who may not be able to join: -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03025074 · State University of New York at Buffalo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2099
🇺🇸 US

Who might be able to join this trial: - Adults and children or teenagers who have a liver disease such as viral hepatitis, liver cancer, or NASH (a condition where fat builds up in the liver and causes damage) - Adults and children or teenagers who do not have a liver disease and would provide comparison (control) bloo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03151473 · Humanity and Health Research Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
Hong Kong

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who are currently being treated or monitored for non-alcoholic fatty liver disease (a condition where fat builds up in the liver, not caused by alcohol) - People who are able to communicate clearly with the research team and are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03190538 · Humanity and Health Research Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇨🇳 CN

Who might be able to join this trial: - You are between 1 and 18 years old and have been diagnosed with NAFLD (a type of liver condition caused by fat buildup) confirmed by a biopsy (a small tissue sample taken from the liver) - Your alcohol consumption is below a certain level — less than 20g per day for boys and less...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03224949 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** This trial includes several different groups of people. You may qualify if you fit into **one** of the following groups: **Group 1 – Alcohol-related fat in the liver (no scarring or inflammation):** - You drink more than 60g of alcohol per day (if male) or more than 40g per d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03308916 · Maja Thiele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇩🇰 DK

**Who might be able to join this trial:** - People aged 30 to 75 years (or 40 to 75 years for those joining as part of the general population group) - People who are able to give their consent to take part in the study - People who are able to read and write in Danish - People who have had, or currently have, a high l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03472157 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 June 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who are willing to give written consent and agree to follow the study procedures before joining. - People with a body mass index (BMI) between 30 and 35 who have a specific level of liver scarring (called F3 fibrosis), confirmed by a liver scan or blood test within th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03535142 · Esbjerg Hospital - University Hospital of Southern Denmark Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2035
🇩🇰 DK

Who might be able to join this trial: - You are over 18 years old. - You have a Body Mass Index (BMI) over 35 (which is considered severely obese) and are scheduled for weight loss surgery at the Hospital of South West Jutland in Denmark, OR you have a BMI over 35 but do not wish to have weight loss surgery. - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03572465 · Centre hospitalier de l'Université de Montréal (CHUM) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇨🇦 CA

Who might be able to join this trial: - People who are at least 18 years old at the time of screening. - People who are able to understand the study and are willing to give their voluntary consent to participate. - People who understand French or English. - *For the NAFLD/NASH group:* People who have a suspected or con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03587831 · University of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 30 and 70 years old. - You have been diagnosed with a liver condition called NASH (a type of fatty liver disease) with results above a certain severity level, AND/OR you have Type 2 diabetes or prediabetes with a recent blood sugar test (HbA1c) below 9%, AND/O...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03811236 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇦🇹 AT

Who might be able to join this trial: - Your body mass index (BMI) is between 28 and 40 (which falls in the overweight to obese range) - More than 10% of your liver is made up of fat, as measured by a scan Who may not be able to join: - You have a hormone or gland disorder (such as thyroid disease that is not being tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03884075 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** **For people with fatty liver disease (main study):** - Adults aged 18 or older - People who have had a liver biopsy in the past 12 months showing fat in the liver, OR have had an imaging scan (such as ultrasound, CT, or MRI) in the past 12 months showing fatty liver disease -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03925701 · Sherief Abd-Elsalam Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with a liver condition called fatty liver disease (NAFLD — where fat builds up in the liver not caused by alcohol) - You have also been diagnosed with type 2 diabetes Who may not be able to join: - You have a liver infection caused by a virus (such as hep...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04036357 · University of Roma La Sapienza Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2036
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with at least one of the following conditions: obesity, diabetes, high blood pressure, or high cholesterol/fats in the blood **Who may not be able to join:** - You drink more than a moderate amount of alcohol daily — sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04054310 · Perspectum Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 75 years old (male or female) - People who are able to understand and sign a written consent form - People who are already scheduled to have a standard liver biopsy using a needle into the right side of the liver, either through the skin or through...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04141592 · Queen Mary University of London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with non-alcoholic fatty liver disease (NAFLD) — a condition where excess fat builds up in the liver — confirmed by a doctor, a scan, or a liver tissue sample - People with NAFLD who also have Type 2 Diabetes may be inc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04190849 · Cambridge University Hospitals NHS Foundation Trust Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 November 2047
🇳🇱 NL🇬🇧 GB

Who might be able to join this trial: - People who were diagnosed with their liver condition before the age of 18. - People who have been diagnosed with a condition on the NAFLD (non-alcoholic fatty liver disease) spectrum, which can include fat in the liver with or without inflammation or scarring. - People whose diag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04232566 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇺🇸 US

**Who might be able to join this trial:** - You are scheduled to have gastric bypass surgery - You have been confirmed to have either no liver scarring (F=0) or significant liver scarring (F greater than 2), based on a specific liver assessment test - You are between 30 and 70 years old - Your Body Mass Index (BMI) is...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04340817 · Copenhagen University Hospital, Hvidovre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇩🇰 DK

Who might be able to join this trial: - People who have been diagnosed with non-alcoholic fatty liver disease - Healthy volunteers (people without any particular health condition) Who may not be able to join: - People who have a liver disease other than non-alcoholic fatty liver disease - People who are unwilling or u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04365855 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who live in Olmsted County at the time of the search - People who are 18 years of age or older - People who have not previously been diagnosed with NAFLD (a type of liver condition caused by fat build-up), based on medical records Who may not be able to join: - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04366999 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are between 16 and 65 years old (any sex) - You have been diagnosed with obesity based on World Health Organization guidelines for Asian populations, and you are already scheduled to have weight-loss (bariatric) surgery at one of the participating hospitals - You have be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04371042 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2035
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years of age or older - You have been diagnosed with a form of non-alcoholic fatty liver disease (NAFLD), which may include simple fat build-up in the liver, liver inflammation caused by fat (NASH), cirrhosis related to metabolism, or liver cancer linked to NAFLD -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04442334 · Newcastle University Not Applicable · 12 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇧🇪 BE🇫🇮 FI🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇹 IT🇳🇱 NL🇵🇹 PT +4 more

**Who might be able to join this trial:** - You must be 18 years of age or older. - You have been diagnosed with, or are suspected to have, a liver condition called NAFLD (a build-up of fat in the liver not caused by alcohol), confirmed by one of the following: a past liver biopsy showing NAFLD; a current or planned l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04496895 · TCI Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇹🇼 TW

Who might be able to join this trial: - Adults between the ages of 20 and 65 who are willing to sign a consent form. - People with a BMI of 24 or higher, or who have fatty liver, and whose body fat percentage is at least 25% (for men) or at least 30% (for women). - People who are not currently pregnant and who are will...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04501406 · University of Florida Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are able to communicate clearly with the research team and can legally sign a consent form on their own behalf. - People aged between 21 and 75 years. - People who have been diagnosed with type 2 diabetes, based on their medical history, diabetes medications they...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04525833 · Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

Who might be able to join this trial: - People who have visited the gastroenterology (digestive health) clinics at the Tzu Chi Hospitals, Buddhist Tzu Chi Medical Foundation Who may not be able to join: - People who are younger than 18 years old or older than 99 years old Important: Always verify eligibility with the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04573283 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 August 2030
🇨🇳 CN

**Who might be able to join this trial:** - You are an adult who has been diagnosed with fat in the liver (called hepatic steatosis), confirmed by at least one of the following: - A liver ultrasound scan that shows a "bright liver" (meaning the liver appears brighter than normal on the scan) - A special ultrasound meas...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04634643 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are in generally good health and are not taking any regular, ongoing medications - People between the ages of 12 and 18 who have gone through or are going through puberty (at a certain stage of physical development known as Tanner stage II–V) - People whose BMI (a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04666402 · Manchester University NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇬🇧 GB

Who might be able to join this trial: - You have been referred to a Community Liver Assessment Clinic. - You are male or female and are over 18 years old. - If you are female, you must not currently be pregnant or breastfeeding. Who may not be able to join: - You are under 18 years of age. - You are currently pregnant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04681573 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 October 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who have been found to have fat buildup in the liver, confirmed by ultrasound, MRI, or a special measurement tool called a Controlled Attenuation Parameter - People whose liver fat is not caused by certain medications (such as steroids, methotrexate, amiodarone, or ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04690972 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 January 2021
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with chronic liver disease (whether caused by a virus or another reason) - People who have at least one liver nodule (a growth or lump on the liver) and are already scheduled to have a biopsy of it as part of their normal medical care - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04697810 · Can-Fite BioPharma Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 15 April 2025
Bosnia and Herzegovina🇧🇬 BG🇮🇱 IL Moldova🇷🇴 RO🇷🇸 RS

**Who might be able to join this trial:** - People who are 18 years of age or older. - People whose liver enzyme levels (AST) are at or above a certain level when tested at screening. - People whose liver stiffness, measured by a special scan called FibroScan, is at or above a certain threshold. - People who have been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04720560 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2024
🇪🇬 EG

Who might be able to join this trial: - Adults older than 18 years old who have been diagnosed with fatty liver disease, based on a physical examination, blood tests, and medical imaging Who may not be able to join: - People who are 18 years old or younger - People who are pregnant - People who have been diagnosed wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04785937 · Azienda USL Reggio Emilia - IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2022
🇮🇹 IT

**Who might be able to join this trial:** - Your doctor has recommended a liver biopsy to check for a condition called NAFLD (fat buildup in the liver), based on specific medical findings - An ultrasound scan has shown that there is fat in your liver - You have at least one risk factor linked to liver disease, such as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04807868 · AdventHealth Translational Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who understand what the study involves and are willing to give written consent to participate *For the Biopsy Group only:* - People who are already scheduled to have a liver biopsy as part of their normal medical care, for any...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04833140 · Massachusetts General Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2027
🇺🇸 US

**Who might be able to join this trial:** - Women who have gone through menopause and are between 45 and 70 years old - People who have been diagnosed with a specific type of liver disease called NASH (confirmed by a liver tissue sample) or a related condition called NAFLD (confirmed by a medical scan) within the past...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04899102 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to give your consent to participate - You are 18 years old or older at the time of signing consent - Your Body Mass Index (BMI) is between 23 and 30 at the screening visit - You have been diagnosed with fatty liver disease (NAFLD), confirmed by a live...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04987879 · Milton S. Hershey Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇺🇸 US

Who might be able to join this trial: - People who are between 18 and 69 years old - People who are largely inactive, doing less than 90 minutes of exercise per week (as measured by a standard activity questionnaire) - People with a body mass index (BMI) above 25 kg/m² (a measure of body weight relative to height) - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05046483 · German Diabetes Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇩🇪 DE

**Who might be able to join this trial:** - People who have recently had a type of heart attack called a STEMI (where a specific pattern shows up on a heart tracing) - People aged 18 to 80 years - People whose blood sugar control measure (HbA1c) is below 9.0% - People who have been diagnosed with diabetes, based on an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05165706 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 35 and 65 years old - Your body weight falls into the overweight to moderately obese range (BMI between 25 and 35) - Your weight has been stable recently - You do not have diabetes **Who may not be able to join:** - You have diabetes - You have a serious dise...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05255978 · Qin Ning Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 June 2023
🇨🇳 CN

Who might be able to join this trial: - People who are older than 18 years of age - People who have been diagnosed with chronic hepatitis B Who may not be able to join: - People who also have chronic hepatitis C, hepatitis D, or HIV - People who drink alcohol heavily (more than 30 grams per day for men, or more than 2...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05275608 · Azienda Ospedaliero Universitaria Maggiore della Carita Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇮🇹 IT

Who might be able to join this trial: - People aged between 25 and 65 years old - People with a body mass index (BMI) between 30 and 40 (a measure of body weight relative to height that falls in the obesity range) - People who have been diagnosed with a liver condition called NAFLD (non-alcoholic fatty liver disease, w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05305287 · The University of Texas Health Science Center at San Antonio Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 March 2027
🇺🇸 US

Who might be able to join this trial: - People who have been confirmed to have type 2 diabetes based on a specific blood sugar test (a 2-hour glucose test showing levels of 200 mg/dl or higher). - People whose diabetes is managed with diet, metformin, and/or a type of medication called a sulfonylurea, and who are in go...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05309863 · University Hospital, Ghent Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇧🇪 BE

**Who might be able to join this trial:** - People who are already enrolled in a lifestyle management program for obesity at one of the participating centres **Who may not be able to join:** - People whose obesity is caused by a specific underlying syndrome or genetic condition - People who have liver disease caused b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05330923 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been newly diagnosed with AIDS or are currently receiving treatment for AIDS - People who are able to attend regular hospital check-up visits and have been taking their medications as directed - People (or their family members) who understand the study plan and ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05332613 · Weill Medical College of Cornell University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 to 64 years old - People with a body mass index (a measure of body weight relative to height) above 25 - People whose liver contains at least 10% fat, as measured by a specific type of MRI scan - People who are willing to sign a consent form and follow the study's...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05385237 · University Hospital, Basel, Switzerland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇭 CH

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with a long-term (chronic) liver condition confirmed by a tissue sample, including fatty liver disease (NAFLD), alcohol-related liver disease, hepatitis B or C, or liver conditions caused by genetic or autoimmune condi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05424003 · University of Virginia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 75 years old (male or female) and have had a liver transplant for any reason (such as fatty liver disease, hepatitis C, alcohol-related liver disease, or autoimmune hepatitis) - Your liver transplant surgery took place between 8 and 24 weeks before joi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05439226 · State Key Laboratory of Subhealth Intervention Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with both type 2 diabetes and a liver condition called NAFLD (a build-up of fat in the liver not caused by alcohol) - People aged between 18 and 75 years old - People with a body mass index (BMI) between 18.0 and 35.0 - People whose weight has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05477212 · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bell... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 May 2024
🇮🇹 IT

**Who might be able to join this trial:** - You have a BMI of 30 or higher, OR a waist measurement greater than 94 cm (about 37 inches) for men or greater than 80 cm (about 31.5 inches) for women, with or without signs of metabolic syndrome - You are between 18 and 70 years old (any sex) - You have been diagnosed with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05480696 · McMaster University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇦 CA

**Who might be able to join this trial:** - Children between the ages of 8 and 17 years old - Children who have been diagnosed with obesity, based on a body weight measurement (BMI) that is significantly above the average for their age and sex according to World Health Organization charts - Children who are already enr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05519475 · Regeneron Pharmaceuticals Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 27 April 2028
🇯🇵 JP Puerto Rico🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older (or the legal age of adulthood in their country) - People who have been diagnosed with a liver condition called MASH (a type of fatty liver disease) with a moderate level of liver scarring, classified as stage 2 or 3 - People whose live...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05526144 · VA Office of Research and Development Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman (before or after menopause) - You are overweight or obese, with a BMI of 25.9 or higher - You drink less than 20 grams of alcohol per day (roughly 1.5 standard drinks) - You have type 2 diabetes and have been on a stable diabetes medication dose for at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05528471 · University of Alberta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇨🇦 CA

**Who might be able to join this trial:** - Boys and girls between 12 and 18 years old who are obese and have been diagnosed with a liver condition called NAFLD (non-alcoholic fatty liver disease) - Participants should be at a mid-to-later stage of puberty (confirm with trial site) **Who may not be able to join:** - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05546086 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 April 2032
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People who are permanent residents of Beijing - People who are willing to sign an informed consent form agreeing to participate **Who may not be able to join:** - No exclusion criteria have been listed for this trial (confirm with tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05554224 · Institut Investigacio Sanitaria Pere Virgili Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇪🇸 ES

Who might be able to join this trial: - People with a Body Mass Index (BMI) of 40 or higher (BMI is a measure of body weight relative to height) - People with a BMI between 35 and 40 who also have at least one of the following conditions: high blood pressure, high cholesterol, or type 2 diabetes - People who have compl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05597709 · Wuxi Hisky Medical Technology Co Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2023
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with Type 2 diabetes according to Chinese medical guidelines for this condition - You have had a specific measurement taken using a device called iLivTouch (confirm with trial site) - You are willing to take part in the study and are able to sign a written...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05618626 · Pontificia Universidad Catolica de Chile Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 April 2025
🇨🇱 CL

Who might be able to join this trial: - People with or without gallstones - People with any degree of NAFLD (non-alcoholic fatty liver disease), ranging from none to severe Who may not be able to join: - People with serious health conditions or physical limitations that would prevent participation in a resistance exer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05623150 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2032
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older. - People who are registered with the French social security system. - People who are able to understand information about the research and sign a written consent form. - People in the **fatty liver disease (NAFLD) group with liver cancer**: those who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05625750 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with non-alcoholic fatty liver disease (a condition where fat builds up in the liver, not caused by alcohol) **Who may not be able to join:** - You are suspected of drinking too much alcohol - You have certain serious health conditions that may preven...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05632861 · Tasly Pharmaceutical Group Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old (inclusive) - People who have had a liver biopsy within the last 6 months (or during the screening process) confirming a specific level of liver disease activity (a NAFLD activity score of 4 or higher, with damage seen across three specific are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05644717 · Getz Pharma Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 November 2025
🇵🇰 PK

**Who might be able to join this trial:** - People who are able to give written consent to participate - Adults aged 18 to 65 years, both male and female - People who have never used SGLT2 inhibitor medications or insulin - People with a BMI greater than 23 kg/m² - People with an HbA1c (a blood sugar measure) between 6...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05648214 · Regeneron Pharmaceuticals Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 August 2027
🇺🇸 US

**Who might be able to join this trial:** *For healthy adults (Part A):* - You are between 18 and 55 years old - You have a body mass index (BMI) — a measure of body weight relative to height — between 18 and 32 - A doctor has reviewed you and considers you to be in good health - Your recent blood test results are wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05697991 · King Saud University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 April 2030
🇸🇦 SA

Who might be able to join this trial: - People who have given their written agreement to participate before any screening takes place - Men and women between 18 and 60 years of age - People who have been diagnosed with type 2 diabetes Who may not be able to join: - People whose liver has stopped working properly, show...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05699018 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected to have, non-alcoholic fatty liver disease (NAFLD) or alcohol-related liver disease (ALD), based on at least one of the following: - People who drink more than 210 grams of alcohol per week (men) or more than 140 grams pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05720663 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults who have cirrhosis (serious scarring of the liver) that has been confirmed either by a liver biopsy or by a specific liver scoring test (called the Agile F score) showing advanced scarring. - People whose liver disease is linked to a fatty liver condition (NAFLD), con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05728697 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You are already scheduled to have an endoscopic ultrasound (a procedure using a camera and sound waves to look inside the body) and a liver biopsy (a procedure where a small sample of liver tissue is taken) as part of your normal medical care -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05766449 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 years or older - People who have tested positive for the hepatitis B surface antigen (a marker showing hepatitis B infection) for at least 6 months, with no other viral infections present at the start of the study - People who have been diagnosed with NAFLD (a cond...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05816915 · General University Hospital, Prague Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇿 CZ

**Who might be able to join this trial:** - You have been diagnosed with non-alcoholic fatty liver disease (a condition where excess fat builds up in the liver not caused by alcohol) and metabolic syndrome (a group of conditions including high blood pressure, high blood sugar, and excess body fat around the waist) **W...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05821010 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 February 2026
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with NASH (a type of fatty liver disease) confirmed by a liver biopsy taken no more than 32 weeks before the study screening, with specific scores for fat, inflammation, and scarring in the liver (confirm with trial site for exact score requirements) -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05832229 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People between 18 and 75 years old. - People whose cirrhosis was caused by nonalcoholic steatohepatitis (a type of fatty liver disease), alcohol-related liver disease, or chronic viral hepatitis B or C that has been treated. - People who have a confirmed diagnosis of cirrhos...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05842512 · Polaris Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - You are a man or a non-breastfeeding woman between 18 and 80 years old with a liver biopsy confirming NASH (a type of fatty liver disease) at a scarring level of F1 to F4 (with F4 being early-stage cirrhosis that is still compensated, meaning the liver is still functioning)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05842850 · Steno Diabetes Center Copenhagen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇩🇰 DK

**Who might be able to join this trial:** - People who have been diagnosed with non-alcoholic fatty liver disease (NAFLD), meaning their liver has been shown to contain 5% or more fat, confirmed by a specific type of scan called MRS during a related screening study **Who may not be able to join:** - People whose BMI (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05870969 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, have been fully informed about the study, and are able to follow all trial procedures - People aged between 18 and 75 years old (including those exact ages) - People who have had a positive hepatitis B surface antigen (a marke...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05881005 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 September 2027
🇫🇷 FR

Who might be able to join this trial: - Adults over 18 years of age - People with active Cushing's syndrome (a condition where the body has too much of the hormone cortisol) Who may not be able to join: - People who have other common causes of long-term liver disease, such as Hepatitis B, Hepatitis C, haemochromatosis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05884723 · Anton Skaro Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 or older who are scheduled to have part of their liver removed (either through open surgery or keyhole surgery) because cancer has spread to the liver from the bowel or rectum - People who have signs of fatty liver disease, shown on a scan (CT or MRI) or a tissue s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05890365 · Steno Diabetes Center Copenhagen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇩🇰 DK

Who might be able to join this trial: - People who were born with a low birth weight (in the bottom 10% compared to the general population) — 250 participants with low birth weight are being recruited, along with 50 participants born with a normal birth weight (between the 50th and 90th percentile) as a comparison grou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05930093 · TCM Biotech International Corp. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇹🇼 TW

**Who might be able to join this trial:** - You are between 20 and 75 years old (male or female) - You are able to give written consent and can communicate clearly with the study team - Your body mass index (BMI) is between 20 and 50, and your weight has been stable for the past 3 months - A special liver scan called a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05935826 · University of Colorado, Denver Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 13 to 18 who are in the later stages of puberty (Tanner stage 4–5) (confirm with trial site) - People who have been suspected of having, or have been diagnosed with, a condition called non-alcoholic fatty liver disease (NAFLD), confirmed by a liver scan or liver t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05974904 · Chongqing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who were part of the NHANES 2017–2020 survey (a large US national health study) - People who have been diagnosed with a liver condition called MAFLD (a type of fatty liver disease linked to metabolic health problems), based on one of the following: - People who have t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05979389 · University of California, San Francisco Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - Women between the ages of 18 and 42 who have been diagnosed with a hormone condition called PCOS that involves higher-than-normal levels of male hormones (androgens) - Women who have a specific type of liver disease called NASH (a form of fatty liver disease with inflammation...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05984745 · Ain Shams University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2025
🇪🇬 EG

**Who might be able to join this trial:** - People aged 18 or older (both male and female) - People who are willing to sign a consent form and agree to follow the study procedures and attend follow-up appointments - People who have at least three out of five signs of metabolic problems: a large waist measurement (102 c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06035874 · Medanta, The Medicity, India Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2024
🇮🇳 IN

**Who might be able to join this trial:** - You are a man or woman aged 20 or older who has been diagnosed with type 2 diabetes for at least 3 months - You are currently taking standard diabetes medications (such as metformin, DPP-4 inhibitors, sulphonylureas, or insulin, alone or in combination) and your blood sugar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06061042 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇳🇱 NL

**Who might be able to join this trial:** - People who are able to give their informed consent to participate in the study. - People with a Body Mass Index (BMI) above 30 kg/m² (a measure that indicates obesity). - People who have insulin resistance (shown by a fasting blood insulin level above 62 pmol/L) and/or predia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06098417 · University of Trieste Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 September 2025
🇮🇹 IT

Who might be able to join this trial: - You have a Body Mass Index (BMI) of more than 35 (a measure of body weight relative to height) - You have been assessed as suitable for weight-loss (bariatric) surgery based on current international medical guidelines Who may not be able to join: - You currently have an active v...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06115876 · Dasman Diabetes Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 May 2027
Kuwait

**Who might be able to join this trial:** - You took part in the original KDEP study previously. - You have been told by a doctor that you have prediabetes (blood sugar levels that are higher than normal but not yet at diabetes level). - You have been diagnosed with Type 2 Diabetes. **Who may not be able to join:** -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06124261 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - People who have a liver condition called metabolic associated steatohepatitis (MASH), which involves liver inflammation linked to fat buildup - People who have polycystic ovary syndrome (PCOS) - People who do not have polycystic ovary syndrome (PCOS) Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06124456 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
Hong Kong

**Who might be able to join this trial:** - People who speak Cantonese, Mandarin, or English and are of Chinese background - People aged between 18 and 69 years old - People who have a larger-than-recommended waist size (90 cm or more for men, 80 cm or more for women) and a body mass index (BMI) of 23 or higher, which...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06133101 · Marialena Mouzaki Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇺🇸 US

Who might be able to join this trial: - Children who are overweight or obese - Children who have a liver condition called non-alcoholic fatty liver disease (NAFLD), confirmed by a specific MRI scan showing fat in the liver above 10% - Children who have either a known diagnosis of NAFLD or elevated liver enzyme levels (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06138821 · Pichamol Jirapinyo, MD, MPH Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older (any gender) - Your body mass index (BMI) is 30 or above, OR your BMI is 27 or above and you have at least one health condition related to your weight (such as high blood pressure or type 2 diabetes) - Your weight has been stable (no more than...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06152250 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 January 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called NAFLD (fat buildup in the liver not caused by alcohol), confirmed by a scan or imaging test, with other causes of liver fat ruled out - You do not drink more than 30g of alcohol per day (if male) or 20g per day (if female...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06186869 · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bell... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2025
🇮🇹 IT

Who might be able to join this trial: - People with a BMI of 30 or higher, or a waist measurement greater than 94 cm for men or 80 cm for women, with or without signs of metabolic syndrome - People between 18 and 65 years of age, of any sex - People who have been diagnosed with fat buildup in the liver (hepatic steatos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06203548 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
Hong Kong

**Who might be able to join this trial:** - A liver scan (MRI) has shown that fat makes up 5% or more of your liver tissue. - You have at least one of the following metabolic health factors: a BMI of 23 or higher; a waist measurement of 90 cm or more (men) or 80 cm or more (women); high fasting blood sugar, high blood...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06206616 · University of Palermo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇮🇹 IT

**Who might be able to join this trial:** - Children who are older than 1 year and younger than 14 years of age - Children who have been diagnosed with Celiac Disease according to recognised European guidelines for children's gut health specialists **Who may not be able to join:** - Children who are 1 year old or youn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06211868 · National University Hospital, Singapore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇸🇬 SG

Who might be able to join this trial: - People who are between 40 and 70 years old - People whose calculated risk score for atherosclerotic cardiovascular disease (a measure of the likelihood of developing heart or blood vessel disease) is 5% or higher Who may not be able to join: - People who have previously had a ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06216041 · Changchun Intellicrown Pharmaceutical Co. LTD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and are able to sign a consent form after fully understanding what the trial involves - You are between 18 and 45 years old (inclusive) - If you are male, you weigh at least 50 kg (about 110 lbs); if you are female, you weigh at least...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06308757 · University of Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 November 2024
🇮🇹 IT

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with NASH (a type of liver disease caused by fat buildup) with signs of liver scarring (fibrosis), confirmed by a tissue sample taken no more than 6 months before joining the trial - People whose weight has been stable for more...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06332677 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇮🇹 IT

**Who might be able to join this trial:** - People over 18 years old whose samples and data were already collected as part of one of three earlier studies (called SERENA, REASON, and MAFALDA), and who previously agreed to genetic analysis - People who agree to take part in this current study **From the SERENA study**...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06335771 · Bettina Mittendorfer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old - You are not currently pregnant or breastfeeding - Your weight has been stable and you have not been doing regular exercise before joining the trial - You do not smoke or use tobacco products, drink excessive amounts of alcohol, or take d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06354088 · Columbia University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 70 years old - People who can understand written and spoken English and/or Spanish - People in the "insulin sensitive" group (Group IS) with a body mass index (a measure of body weight relative to height) between 18 and 25 - People in the "insulin resis...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06355310 · Justin Ryder Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - You have a BMI over 30, or your BMI is above the 95th percentile for your age group - You weigh between 75 kg and 150 kg (approximately 165 to 330 pounds) - You are between 16 and 20 years old at the start of the study - You have either an elevated liver enzyme level (ALT) d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06368882 · First Affiliated Hospital of Wenzhou Medical University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 60 years old (men or women, including those exactly 18 or 60) - People who have been diagnosed with both chronic hepatitis B and fatty liver disease, according to specific Chinese medical guidelines - People who have tested positive for a hepatitis B surfac...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06374875 · Ali Aminian Phase 4 · 13 countries Recruiting
Recruiting Phase 4 Est. completion 31 May 2029
🇧🇷 BR🇨🇦 CA🇫🇮 FI🇮🇳 IN🇮🇪 IE🇮🇹 IT Kuwait🇲🇽 MX +5 more

**Who might be able to join this trial:** - People who are considered a suitable candidate for general anaesthesia - People who qualify for weight loss (metabolic) surgery — specifically a gastric bypass (RYGB) or sleeve gastrectomy (SG) — based on current international guidelines - People who have insurance coverage...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06386094 · Post Graduate Institute of Medical Education and Research, Chandigarh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2027
🇮🇳 IN

**Who might be able to join this trial:** - People between 18 and 65 years of age - People who have been diagnosed with a liver condition called metabolic dysfunction associated steatotic liver disease (a type of fat-related liver disease), confirmed through a liver tissue sample, blood tests, ultrasound scan, or a spe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06396871 · Technische Universität Dresden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇪 DE

**Who might be able to join this trial:** - You must be over 18 years old. - You may join as a **"case" participant** if you fall into one of these groups: - **Liver scarring risk group:** You have both a FIB-4 score of 1.3 or higher AND a liver stiffness scan result of 8 kPa or higher (confirm with trial site). -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06449833 · Zhujiang Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with type 2 diabetes within the last 5 years - You are willing to take part, understand what the trial involves, and are happy to sign a consent form and follow all study requirements - Your blood sugar is managed either through diet and exercise alon...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06453915 · University of California, Davis Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have had, or are planning to have, a liver biopsy as part of standard medical care for fatty liver disease with risk factors for a condition called MASH, OR as part of another clinical trial for MASH, OR as standard care before...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06461208 · King's College London Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 January 2028
🇬🇧 GB

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with liver cirrhosis caused by alcohol use, a condition called MASLD (fat-related liver disease), or a combination of both, confirmed by medical tests, scans, or a liver biopsy - Your liver disease is rated at a moderate...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06477146 · University Hospitals Cleveland Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 9 and 22 years old and have been diagnosed with non-alcoholic fatty liver disease (NAFLD). - Your liver enzyme levels (called ALT) are higher than normal — specifically above 50 U/L for boys or above 44 U/L for girls. - You are either overweight or obese base...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06493799 · Green Cross Wellbeing Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2026
🇰🇷 KR

**Who might be able to join this trial:** - People who are between 19 and 70 years old at the time of screening - People who have been diagnosed with alcoholic or non-alcoholic fatty liver disease - People whose ALT liver enzyme level (a measure of liver health) falls between 60 and 200 IU/L at the time of screening -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06495333 · Fundacion de Investigacion Science and Education Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 December 2024
Puerto Rico

**Who might be able to join this trial:** - People of Hispanic ethnicity who currently live in Puerto Rico - People between 21 and 75 years old at the time of signing consent to participate - People who have evidence of a specific liver condition called MASLD, shown by a scan result (FibroScan) meeting a particular thr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06503068 · Tanta University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇪🇬 EG

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with fatty liver disease (also known as NAFLD or NASH) and are willing to complete a survey. - Doctors who treat patients with fatty liver disease, including liver specialists, digestive health specialists, hormone specialists, and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06508190 · Ahram Canadian University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇪🇬 EG

"Who might be able to join this trial: - People with a body mass index (BMI) under 35 kg/m² (a measure of body weight relative to height) - People who have been diagnosed with obstructive sleep apnea (a sleep condition where breathing repeatedly stops and starts during sleep) and also have a fatty liver Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06512701 · First Affiliated Hospital of Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older, of any gender - People who are willing to take part voluntarily and sign a consent form - People who have been diagnosed with non-alcoholic fatty liver disease (NAFLD) through an abdominal ultrasound scan Who may not be able to join: - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06519162 · Chungnam National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 July 2029
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 19 or older who have been diagnosed with one of the following liver conditions: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, and who agree to take part in the study at Chung...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06523179 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with non-alcoholic fatty liver disease (NAFLD) or a liver disease of unknown cause, and you drink no more than about 4 drinks per day (men) or about 2.5 drinks per day (women) - You are between 45 and 75 years old - You have significant liver scarring...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06541132 · Chongqing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 April 2025
🇨🇳 CN

Who might be able to join this trial: - You must be older than 18 years of age - You must have had a coronary angiography (a procedure to look at the blood vessels of the heart) at the study hospital between August 2022 and December 2023, due to chest pain, chest tightness, or other reasons Who may not be able to join...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06564584 · OrsoBio, Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇲🇽 MX

Who might be able to join this trial: - People with a body mass index (BMI) of 28 or higher at the screening visit - People with high fasting triglyceride levels (a type of fat in the blood) of 350 mg/dL or above - People without diabetes, or people with diabetes whose blood sugar control (HbA1c) is below 9.5% - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06566105 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2030
🇮🇹 IT

**Who might be able to join this trial:** - People who are blood donors between the ages of 40 and 65 - People who have been clinically identified as overweight or obese (meaning a body mass index, or BMI, above 25) - People who have at least one of the following: higher-than-normal fasting blood sugar levels or type 2...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06567990 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 May 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with type 2 diabetes - People aged between 40 and 80 years old - People who have been found to have fat build-up in the liver (hepatic steatosis), confirmed by a standard abdominal ultrasound scan, as defined by European liver disease guideline...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06569524 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part and sign a consent form agreeing to participate. - People aged 18 to 74 years old at the time of signing the consent form. - People who have had a liver biopsy within the past 180 days showing a specific level of liver scarring (fibrosis stage...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06571474 · Bettina Mittendorfer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 70 years old - People who are not currently pregnant or breastfeeding - People whose weight has been stable and who have not been doing regular exercise before enrolling - People who do not use tobacco products, drink excessive amounts of alcohol, take diet...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06585982 · Universitas Diponegoro Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 March 2025
🇮🇩 ID

**Who might be able to join this trial:** - People between 25 and 55 years old - People who are willing to sign a consent form agreeing to take part as a research participant - People who are able and willing to take supplements by mouth at set times throughout the study - People who are willing to keep a diary to reco...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06588699 · Yale University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People whose body weight has been stable (changed by no more than 5% by their own report) in the 30 days before the screening visit - People who have a confirmed liver condition called non-alcoholic steatohepatitis (NASH), diagnosed through a liver biopsy taken within 6 mont...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06591169 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇪🇬 EG

**Who might be able to join this trial:** - You are a woman (the trial includes forty women in total) - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), a hormonal condition affecting the ovaries - You have been diagnosed with obstructive sleep apnea, a condition where breathing repeatedly stops and start...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06596109 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2025
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with fatty liver disease (the non-alcohol-related form) - Both men and women are included - People who are classified as Class I obese (confirm with trial site for the specific weight or BMI range this refers to) Who may not be able to join: - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06599918 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇪🇸 ES

Who might be able to join this trial: - Adults between 18 and 85 years of age. - People who have been diagnosed with non-alcoholic fatty liver disease (a condition where fat builds up in the liver, not caused by alcohol) by their doctor. - People with a body mass index (a measure of body weight relative to height) betw...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06619808 · Jinling Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with metabolic dysfunction-associated steatotic liver disease (a condition where fat builds up in the liver linked to metabolic health issues). Who may not be able to join: - People who are not medically suitable for hyperbaric treatment (a therapy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06626074 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 September 2027
🇫🇷 FR

Who might be able to join this trial: - People who are already part of the SNIFF patient group at Angers hospital, where fatty liver disease (NASH) is suspected and a liver biopsy and MRI scan have been requested by a liver specialist as part of their initial assessment - People who are adults (18 years of age or older...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06649162 · Boryung Pharmaceutical Co., Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇰🇷 KR

**Who might be able to join this trial:** - You have type 2 diabetes and your doctor is planning to start you on a combination pill containing dapagliflozin and pioglitazone at your first study visit. - You are willing to voluntarily sign a written agreement allowing your personal information to be used for this study,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06661655 · E-Scopics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 to 79 years old - People with a liver condition called MASLD or MASH who are already taking part in another clinical trial that requires specific liver imaging scans (MRI PDFF and/or MRE) - People with MASLD or MASH who are already enrolled in a research follow-up...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06671886 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇺🇸 US

Who might be able to join this trial: - Care teams (called Patient Aligned Care Teams, or PACTs) that work at the Michael E. DeBakey VA Medical Center may be eligible to participate. Who may not be able to join: - Care teams where the leadership is unstable at the time the trial begins — for example, if a key leader i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06694935 · 1Globe Health Institute Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2025
🇨🇦 CA

**Who might be able to join this trial:** - You are between 18 and 64 years old - Your body weight falls within a healthy to moderately obese range (BMI between 18 and 44.9) - You have been diagnosed with Type 2 diabetes according to 2021 American Diabetes Association guidelines - You have been diagnosed with a liver...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06704321 · Valbiotis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇦 CA

Who might be able to join this trial: - Adults between 18 and 75 years old (inclusive) - People whose liver scan (FibroScan®) shows a high level of fat in the liver (CAP Score ≥288 dB/m) but low levels of liver stiffness, suggesting little to no scarring (fibrosis score F0 to F1, below 8 kPa) - People with a body mass...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06704516 · University of Oxford Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 5 August 2025
🇬🇧 GB

**Who might be able to join this trial:** - People who are willing and able to give informed consent to take part in the trial - People who are willing and able to follow all trial requirements, in the opinion of the trial investigator - Women aged 18 years or older - People with a body mass index (a measure of weight...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06705998 · BAR Pharmaceuticals s.r.l. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 May 2026
🇨🇭 CH

**Who might be able to join this trial:** - People aged 18 to 55 years old (men and women) - People with a body weight in a healthy range for their height, specifically a Body Mass Index (BMI) between 18.5 and 30 - People with blood pressure and heart rate within normal ranges when measured after sitting quietly for 5...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06707129 · Beijing Municipal Administration of Hospitals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old at the time of your liver biopsy - Any gender may participate - Your liver biopsy results show NASH (a type of fatty liver disease caused by fat buildup, not alcohol) along with moderate to severe liver scarring (stage F2 to F4) - You are w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06717828 · Fujian Provincial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 40 and 75 years old - A scan has shown that your liver contains 5% or more fat - You have been diagnosed with fatty liver disease linked to metabolic health problems (sometimes called MAFLD or metabolic-associated fatty liver disease) - You are overweight or o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06720766 · The Third People's Hospital of Chengdu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older and have agreed in writing to take part in the study - You are already planning to have weight-loss (bariatric) surgery and a liver biopsy to check for a suspected liver condition called MASLD (a type of fatty liver disease) - You are already sch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06735118 · Yunnan Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇨🇳 CN

Who might be able to join this trial: - CT scan or abdominal ultrasound results showed no fatty liver - No reasons that would prevent an MRI scan, such as having a pacemaker, stent, or metal implant in the body, or having claustrophobia (fear of enclosed spaces) - Has received chemotherapy either before or after surger...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06739330 · Tanta University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇪🇬 EG

Who might be able to join this trial: - People who are 18 years of age or older - People of any sex - People who have been diagnosed with a liver condition called metabolic dysfunction-associated fatty liver disease (MAFLD), which is a type of fat buildup in the liver linked to metabolic health issues Who may not be a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06751862 · Institute for Clinical and Experimental Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇨🇿 CZ

**Who might be able to join this trial:** **Part A:** - Male volunteers aged 18 to 70 years old - Either non-obese (with a body mass index — a measure of body weight relative to height — below 30) or obese (with a body mass index above 30) **Part B:** - Male volunteers aged 18 to 70 years old - People with a liver fa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06798948 · Li Lab,MD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with metabolic-associated fatty liver disease with mild to moderate fatty liver. - You are between 18 and 65 years old (any gender). - You have not taken any liver-protecting medications in the past 3 months. - You are willing to sign a consent form an...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06802731 · Wuxi Hisky Medical Technology Co Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with non-alcoholic fatty liver disease (NAFLD) according to specific American liver disease guidelines - People who are 18 years of age or older (any gender) - People who do not have other liver conditions, such as viral hepatitis, liver damage from...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06803108 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2025
🇪🇬 EG

"Who might be able to join this trial: - People who have been diagnosed with fatty liver disease - People who are living with obesity - People whose obesity falls into the Class 1 category (confirm with trial site for exact measurement criteria) Who may not be able to join: - People who have heart or cardiovascular-re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06814600 · Centre Hospitalier Universitaire Saint Pierre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇧🇪 BE

Who might be able to join this trial: - People who have been diagnosed with Inflammatory Bowel Disease (IBD), confirmed through clinical assessment, a camera examination of the bowel, and tissue analysis, following current international IBD guidelines. - People who are willing to give their consent to take part in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06819917 · Roche Diagnostics GmbH Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇩🇰 DK🇩🇪 DE

**Who might be able to join this trial:** - People who are scheduled for a liver biopsy, or who had a liver biopsy between 1 and 6 months ago (for those with early-stage liver scarring), where the biopsy relates to suspected liver scarring caused by a fatty liver condition (NAFLD, NAFL, NASH, MASLD, or MASH) - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06843148 · Université de Sherbrooke Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇨🇦 CA

**Who might be able to join this trial:** - People aged 20 to 80 years - People who have been diagnosed with a liver condition called MASLD, which is defined as having fat in the liver combined with excess abdominal fat, measured using international guidelines specific to their country or ethnic background **Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06856252 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2030
🇮🇹 IT

**Who might be able to join this trial:** - Adults who have agreed to take part and are scheduled for a liver biopsy because doctors suspect a condition called non-alcoholic steatohepatitis (a type of liver disease caused by fat build-up, not alcohol) at the time of first diagnosis - Adults who are scheduled for surge...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06863376 · Tanta University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 March 2027
🇪🇬 EG

Who might be able to join this trial: - You are an adult (over 18 years old), male or female, and have been diagnosed with fatty liver disease through an abdominal ultrasound scan Who may not be able to join: - Women who are pregnant or currently breastfeeding - People who drink more than a certain amount of alcohol r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06873165 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

**Who might be able to join this trial:** - People aged between 20 and 70 years old (male or female) - People who have been diagnosed with liver fat accumulation through a specific scan called FibroScan, with a result of CAP 260 or higher - People who also meet at least one of the following conditions: - A body mass i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06879236 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with a liver condition called MASLD (a type of fatty liver disease) and a liver stiffness measurement of 10 kPa or higher (a result from a special scan that checks liver health) - You are 18 years old or older - You are comfortable using digital device...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06883578 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 16 and 80 years old (male or female) - Your Body Mass Index (BMI) is 24 or higher (this means your weight is in the overweight or obese range based on your height) **Who may not be able to join:** - You drink heavily — for men, more than 140g of alcohol per w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06888310 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older (any sex) - You have been diagnosed with a liver disease related to metabolic problems (such as fatty liver disease linked to obesity, diabetes, or similar conditions), based on the latest medical definitions - A special ultrasound scan of you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06890169 · Changi General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇸🇬 SG

**Who might be able to join this trial:** - You are an adult between 21 and 70 years old - Your Body Mass Index (BMI) — a measure of body weight relative to height — is above 27.5 - Your waist measurement is greater than 90 cm (about 35.5 inches) if you are a man, or greater than 80 cm (about 31.5 inches) if you are a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06920043 · GlaxoSmithKline Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 July 2028
🇺🇸 US

Who might be able to join this trial: - People who are able to understand and sign a written consent form agreeing to take part in the trial - People who are between 18 and 75 years of age at the time of joining - People who have, or have had, at least 2 out of 5 features of a condition called metabolic syndrome (a gro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06939569 · Shanghai East Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any sex - People who have been diagnosed with Inflammatory Bowel Disease (IBD) according to Chinese medical guidelines for diagnosing and treating this condition - People who are able to attend follow-up appointments, take part in the study, and sign a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06947304 · Corcept Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2026
🇺🇸 US

**Who might be able to join this trial:** - Your blood test shows a certain level of a liver enzyme called AST — above 17 U/L if you are a woman, or above 20 U/L if you are a man (this requirement may not apply if you had a qualifying liver biopsy within the last 12 months — confirm with trial site). - A special liver...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06975579 · Institute of Cancer Research, United Kingdom Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇬🇧 GB

Who might be able to join this trial: **Healthy Volunteers:** - Adults aged 18 or older who consider themselves fit and healthy - People who are current employees of the Royal Marsden Hospital (RMH) and/or the Institute of Cancer Research (ICR) **Patients:** - Adults aged 18 or older who are already having a liver MR...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07051863 · Fondazione Epatocentro Ticino Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇭 CH

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who are willing to sign a consent form and complete all study visits and procedures - People who have been diagnosed with a liver condition known as NAFLD, NASH, or MAFLD, confirmed thro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07068191 · Phenomen Pharma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇷🇺 RU

Who might be able to join this trial: - People aged between 18 and 65 years old - People who have been diagnosed with a condition called metabolic-associated fatty liver disease (MAFLD), which is a type of liver disease linked to metabolism problems - People whose liver is enlarged by a certain amount, confirmed by an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07070362 · Beijing Tsinghua Chang Gung Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

Who might be able to join this trial: - You are 18 years old or older - You are scheduled to have a major liver surgery, such as removal of two or more sections of the liver, or a liver transplant - You are willing to take part and have signed a consent form agreeing to join the study Who may not be able to join: - No...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07083336 · State Key Laboratory of Subhealth Intervention Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with both type 2 diabetes and a liver condition called NAFLD (a build-up of fat in the liver not caused by alcohol) - People aged between 18 and 75 years old - People with a body mass index (BMI) above 18.0 (a measure of weight relative to heig...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07093346 · University of Nottingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇬🇧 GB

**Who might be able to join this trial:** **Main study participants:** - You have been diagnosed with a liver condition called MASLD (also known as fatty liver disease), with test results showing more than 5% fat in your liver from a scan or biopsy done recently. - You are willing and able to sign a consent form agree...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07099118 · Sunshine Lake Pharma Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to follow the study procedures, participate voluntarily, and sign a consent form agreeing to take part. - People aged between 18 and 45 years old (inclusive) at the time of signing the consent form — both males and females are eligible. - Male particip...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07122700 · Foundation for the National Institutes of Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part in the study - People who are willing to follow all study procedures and are available for the full length of the study - People aged between 18 and 75 years (male or female) - People who show signs of met...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07128797 · Tasly Biopharmaceuticals Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People of Chinese background aged between 18 and 75 years - People who have been diagnosed with non-alcoholic fatty liver disease (a condition where too much fat builds up in the liver), confirmed by a specific type of liver fat scan (MRI) showing fat levels of 10% or more,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07130318 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 January 2026
🇪🇬 EG

Who might be able to join this trial: - Women who have been diagnosed with Familial Mediterranean Fever - Women who are classified as obese - Women who have non-alcoholic fatty liver disease Who may not be able to join: - People with a heart condition - People with a respiratory (breathing-related) disease - People wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07149571 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2032
🇨🇳 CN

Who might be able to join this trial: - People who have been referred for an MRI scan and are suspected or confirmed to have metabolism-related fatty liver disease - People of any age or gender - People who are willing to take part in the clinical trial and have signed a written consent form Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07185932 · Shanghai Changzheng Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part - You are between 18 and 75 years old (any gender) - You have been diagnosed with fatty liver disease within the last 6 months - You have at least one of the following: you are overweight or obese (BMI of...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07193927 · AB Biotics, SA Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇪🇸 ES

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People with a body mass index (a measure of body weight relative to height) between 25 and 42 - People who have been diagnosed with a liver condition called MASLD, confirmed by a specific liver scan (FibroScan®) showing a result abov...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07198386 · Cascade Pharmaceuticals, Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 July 2026
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 70 years old (inclusive) of any gender. - People who have had a liver biopsy within the past 6 months showing a diagnosis of NASH (a type of fatty liver disease) with a disease activity score of 4 or higher and a specific level of liver scarring (F1–F3), OR...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07214870 · Novo Nordisk A/S Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 14 May 2027
🇨🇦 CA

**Who might be able to join this trial:** - People who are between 18 and 69 years old (inclusive) at the time of signing the consent form - People whose Body Mass Index (BMI — a measure of weight relative to height) falls between 27.0 and 40.0 at the screening stage - People whose liver contains 8% or more fat, as mea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07221188 · GlaxoSmithKline Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 24 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are able and willing to read, understand, and sign a written consent form before any study procedures begin - People aged 18 to 75 years old at the time of enrolment - People who have, or have had, 2 or more of the 5 features of metabolic syndrome, as defined by th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07237750 · Liu Yan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are Asian and between 18 and 65 years old. - Your body weight falls within a specific range based on your height, with a BMI between 24.0 and 37.4 (using Chinese health standards). - You have already tried to lose weight through diet or lifestyle changes for at least 2 mo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07238985 · Tanta University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 November 2026
🇪🇬 EG

**Who might be able to join this trial:** - Adults over 18 years old (male or female) who have been diagnosed with fatty liver disease, confirmed through an ultrasound scan of the upper abdomen **Who may not be able to join:** - Women who are pregnant or breastfeeding - People who drink more than 30 grams of alcohol p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07241195 · The Affiliated Hospital of Hangzhou Normal University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People aged 65 or older who have lived permanently in the study area for more than 5 years - People who have been diagnosed with fatty liver through an imaging scan (such as an ultrasound or a liver stiffness scan like FibroScan or FibroTouch) - People who are willing to take par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07242222 · Tanta University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 November 2026
🇪🇬 EG

Who might be able to join this trial: - You are an adult aged 18 or over (male or female) - You have been diagnosed with fatty liver, confirmed by an ultrasound scan of your upper abdomen Who may not be able to join: - Women who are pregnant or currently breastfeeding - People who drink more than a certain amount of a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07246421 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇩🇰 DK

**Who might be able to join this trial:** - Your Body Mass Index (BMI) — a measure of body weight relative to height — is above 26 kg/m² - You have been officially diagnosed with Type 2 Diabetes for at least 6 months before joining the trial - For one specific group in the trial: a special liver scan (MRI) has shown t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07248371 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇹🇼 TW

Who might be able to join this trial: - You are a man or woman aged 20 years or older - You are willing and able to sign a written consent form agreeing to take part in the study Who may not be able to join: - You are currently pregnant or breastfeeding - You have severe kidney disease and are receiving dialysis treat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07265297 · National Taiwan University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇹🇼 TW

Who might be able to join this trial: - People who are at least 18 years old. - People who are able to attend scheduled check-up visits at specific points over the 12-month study period. - People who have been diagnosed with fatty liver, confirmed by an ultrasound or MRI scan of the abdomen. - People who have signs of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07265544 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and signed a consent form - People of any age or gender are eligible to be considered - People who have been diagnosed with a liver haemangioma (a benign growth made up of blood vessels in the liver) or focal nodular hyperplasia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07270601 · ContextVision AB Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** **If you have a liver condition or are at risk:** - You are between 18 and 75 years old - You are willing to give your consent to take part in the study - You have been diagnosed with or are suspected to have a fatty liver condition (called MASLD) by a liver specialist, OR you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07272343 · Second Affiliated Hospital of Nanchang University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old - People with a body mass index (BMI) of 25 or higher (a measure of body weight relative to height) - People who have been diagnosed with type 2 diabetes according to specific Chinese medical guidelines (2020 Edition) - People whose HbA1c (a blood t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07288138 · Eccogene Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 to 75 years who are able to give written consent and follow the study requirements - People with a suspected diagnosis of a liver condition called MASH, confirmed either by a liver biopsy taken within the last 6 months showing certain scores, or by a liver sca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07294963 · Khyber Medical University Peshawar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 April 2026
🇵🇰 PK

Who might be able to join this trial: - People between 18 and 42 years of age. - People who have been diagnosed with fatty liver disease (also called NAFLD) using an imaging test such as an ultrasound. - People who have had their liver stiffness (fibrosis) measured and graded using a FibroScan test and a blood-based sc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07308548 · Hinova Pharmaceuticals Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 13 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to give their written agreement to take part after being fully informed about what the trial involves, including possible side effects. - People who are between 18 and 65 years old (including those exact ages). - People whose liver fat level is measure...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07321925 · Endra Lifesciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who are able to read, understand, and sign a consent form written in English. - People who are able to tolerate both ultrasound and MRI scans. - People who are able to lie flat or on their side for 20 minutes and hold their br...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07330830 · Centre Hospitalier Universitaire de la Guadeloupe Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 26 November 2027
French Guiana Guadeloupe Reunion

Who might be able to join this trial: - You are 18 years old or older and have been seen in an outpatient clinic or are currently admitted to the liver and digestive department at one of the University Hospitals in Guadeloupe, French Guiana, or Réunion Island. - You have been diagnosed with a liver condition called MAS...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07335198 · GlaxoSmithKline Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 17 August 2026
🇳🇿 NZ

**Who might be able to join this trial:** - You are generally in good health, as confirmed by a medical check-up - You weigh at least 50 kg (about 110 lbs) if you are male, or at least 45 kg (about 99 lbs) if you are female - Your Body Mass Index (BMI — a measure of body weight relative to height) is between 18.0 and...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07358546 · GlaxoSmithKline Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 13 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old (inclusive) - Your Body Mass Index (BMI) is between 23 and 40 (a measure of body weight relative to height) - You can be male or female - You have been diagnosed with liver cirrhosis (scarring of the liver), confirmed by a previous liver bi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07403604 · Columbia University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 65 years old - People with a body mass index (a measure of weight relative to height) between 30 and 45 - People who can read and speak English and/or Spanish - People who are able to have their initial blood tests done and get started in the study with...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07481734 · Hudson Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old and able to give your consent to participate - Imaging tests (such as an MRI) show that you have a significant amount of fat in your liver, consistent with a condition called MASLD or NAFLD - Tests suggest your liver scarring (fibrosis) is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07518784 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with, or are suspected by a doctor to have, a liver condition called MASLD (a type of fatty liver disease) - People with a body mass index (BMI) between 27 and 45 at the time of being referred to the study - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07527910 · Regeneron Pharmaceuticals Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 March 2030
🇺🇸 US

Who might be able to join this trial: - People who carry two copies of a specific gene variant called PNPLA3 p.I148M (one inherited from each parent) - People whose liver contains 15% or more fat, as measured by a specific type of MRI scan called MRI-PDFF - People with a Body Mass Index (BMI) of 30 or above but below 4...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07534241 · University of Lahore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇵🇰 PK

Who might be able to join this trial: - Adults between the ages of 35 and 65 years old. - People with a body weight in a range considered neither underweight nor overweight, based on a standard height-to-weight calculation (BMI between 18.5 and 30). - People whose routine blood count results fall within certain ranges...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07541469 · Madrigal Pharmaceuticals, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 April 2030
🇺🇸 US

Who might be able to join this trial: - Female patients with a liver condition called NASH (a type of fatty liver disease) who took at least one dose of a medication called resmetirom either during pregnancy (including within 3 days before becoming pregnant) or while breastfeeding, and/or their babies up to 12 months o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07553663 · Corcept Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 October 2026
🇺🇸 US

**Who might be able to join this trial:** - Your liver has been assessed using a special scan (FibroScan) showing signs of liver stiffness and fat, OR you have had a liver biopsy within the last 12 months showing a certain level of liver inflammation, fat, and scarring. - Your liver enzyme levels (a blood test called...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07599241 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2026
🇪🇬 EG

**Who might be able to join this trial:** - You have been diagnosed with a mild, early-stage underactive thyroid (a condition where the thyroid is not working fully but may not yet cause obvious symptoms) - You have a type of glaucoma called primary open-angle glaucoma in both eyes, where the pressure inside both eyes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07632677 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any sex - People who have been diagnosed with a liver condition called metabolic dysfunction-associated fatty liver disease (MAFLD) according to specific Chinese medical guidelines (confirm with trial site) - People who have also been diagnosed wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07646197 · Henry Ford Health System Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 April 2028
🇺🇸 US

**Who might be able to join this trial:** - You are between 30 and 70 years old - You eat peanuts, peanut butter, tree nuts, or seeds less than once a week (or not at all) - You have been diagnosed with a mild form of a liver condition called MASLD (also known as metabolic dysfunction-associated steatotic liver disease...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07658755 · Hospital General Universitario Gregorio Marañon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇪🇸 ES

**Who might be able to join this trial:** - People aged between 50 and 75 years old (inclusive) - People who have had a routine blood test done through the Clinical Biochemistry Laboratory at Hospital General Universitario Gregorio Marañón, ordered by a primary care doctor from one of the 11 linked primary care centre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07662356 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 October 2028
Hong Kong

Who might be able to join this trial: - People who are 18 years of age or older - People of Chinese ethnicity - People who are having obesity (weight loss) surgery at The Prince of Wales Hospital Who may not be able to join: - People whose obesity is caused by a hormonal or glandular condition - People with an active...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07679542 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 45 years of any gender. - People who have been diagnosed with Metabolic Associated Fatty Liver Disease (MAFLD), which requires evidence of fat in the liver shown by at least one of: an ultrasound, CT scan, or MRI showing liver fat of 5% or more; a liver biopsy t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07692438 · Taipei Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇹🇼 TW

**Who might be able to join this trial:** - Adults between 18 and 80 years of age - People who have been diagnosed with fatty liver (a condition where fat builds up in the liver), confirmed by an abdominal ultrasound scan - In addition to fatty liver, people who also have at least one of the following health character...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Non-Alcoholic Fatty Liver Disease. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Fatty liver disease falls under the Liver Foundation's national work on liver health.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.